Optimizing gemcitabine regimens in ovarian cancer.


Ovarian cancer represents the leading cause of death from gynecologic neoplasms. The chance of response to secondary treatment is currently disappointing; few agents have shown notable activity in recurrent/progressive patients. Among these agents, gemcitabine represents one of the most interesting newer antineoplastic agents, showing significant activity… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.